Shots:

• The P-II GEOMETRY mono-1 study results involves assessing of Capmatinib (400mg- bid) in 97 treatment-naive & prior treated patients with LA/metastatic NSCLC harboring a MET exon-14 skipping mutation
• The P-II GEOMETRY mono-1 study results:  ORR based on BIRC assessment / RECIST v1.1 (68% & 41%); DOR (11.14 mos. & 9.72 mos.)- 54% patients showed intracranial activity- presented at ASCO 2019
• Capmatinib (INC280) is an oral & selective MET inhibitor- licensed by Novartis from Incyte Corporation in 2009 and has received FDA’s BT designation for m-NSCLC with MET exon-14 skipping mutation. Additionally- Novartis presents data of canakinumab (ACZ885) as monothx. in P-III CANOPY study for mid- to late-stage NSCLC

Ref: Novartis | Image: Creative Concept Design